To the best of our knowledge, this is the first study demonstrating that ART has potential as an anti-tumor agent for metastatic RCC, and also identifies TfR1 as a potential marker for predicting the effect of ART on RCC cells. Here, TFRC is linked to renal cell carcinoma.